Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus platinum-based doublet chemotherapy as neoadjuvant therapy for resectable stage III NSCLC
ChiCTR2000040001Phase 4Recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Xuzhou Central Hospital. Primary endpoint: Major pathologic response (MPR) rate. Started Nov 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000040001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040001.